5-溴-1-四氢萘酮 | 68449-30-9

• 物质功能分类: 化学试剂 - 有机试剂 - 多环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 5-溴-1-四氢萘酮
• 中文别名: 5-溴四氢萘酮(MP:49-52)；5-溴-Α-四氢萘酮；5-溴-3,4-二氢-2H-萘-1-酮
• 英文名称: 5-bromo-1-tetralone
• 英文别名: 5-bromo-3,4-dihydronaphthalen-1(2H)-one；5-bromotetralone；5-bromotetralin-1-one；5-bromo-3,4-dihydro-2H-naphthalen-1-one
• CAS: 68449-30-9
• 化学式: C₁₀H₉BrO
• mdl: MFCD02179288
• 分子量: 225.085
• InChiKey: DMXOUYZZHVHEQR-UHFFFAOYSA-N

物化性质

• 熔点：
  47-48 °C(Solv: methanol (67-56-1))
• 沸点：
  105-110 °C(Press: 0.3 Torr)
• 密度：
  1.511±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：10mg/mL； DMSO：10mg/mL；乙醇：2mg/mL； PBS（pH 7.2）：0.15 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：室温、密封、干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-1-tetralone
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-1-tetralone
CAS number: 68449-30-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H9BrO
Molecular weight: 225.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

四氢萘酮类化合物是一类重要的中间体，在医药、化工、新材料和高分子领域广泛应用。例如，四氢萘酮是合成抗抑郁药舍曲林的重要前体；6-甲氧基-1-萘酮则是合成计划生育药物18-甲基炔诺酮和左炔诺孕酮等甾体药物的关键中间体。氮杂萘酮同样在新材料和高分子领域中发挥着重要作用。

作为四氢萘酮类化合物的一种，5-溴-1-四氢萘酮是合成选择性5-HT6受体拮抗剂的重要中间体，该拮抗剂具有潜在的治疗中枢神经系统失调（如帕金森症）的作用。

制备

5-溴-1-四氢萘酮可通过从5-氨基-1-四氢萘酮出发，经过桑德迈尔反应制得。然而，目前市场上尚无大量商品供应。现有的合成路线主要分为两类：第一种方法是先将5-甲氧基-1-四氢萘酮经水解得到5-羟基-1-四氢萘酮，再通过烷基化-Smiles重排-水解反应制备，但该方法不适合大规模生产；第二种是以苯甲酰基丙酸为原料，经过混酸硝化、催化氢化还原硝基后乙酰基保护、还原羰基后的傅克酰基化关环得5-乙酰氨基-1-四氢萘酮。此路线虽然总收率较低，并且混酸硝化会产生大量废酸，但开发一条原料价廉易得且产率高的合成路线仍十分必要。

本文提出了一种以成本低廉、易于获取的四氢萘为原料的方法：通过与乙酰氯进行傅克酰基化反应得到5-乙酰基四氢萘；再经盐酸羟胺反应生成肟，随后进行贝克曼重排得到5-乙酰氨基四氢萘；经过氧化处理后得到5-乙酰氨基-1-四氢萘酮；最后通过水解直接进行桑德迈尔反应得到目标产物5-溴-1-四氢萘酮。此路线原料易得、操作简便，适合大规模生产。合成路线如图1所示。


反应信息

• 作为反应物：
  描述：

  5-溴-1-四氢萘酮 在 甲醇 、 sodium tetrahydroborate 、 碳酸氢钠 、 对甲苯磺酸 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 甲苯 、 苯 为溶剂， 反应 3.75h， 生成 5-溴-3,4-二氢-1H-2-萘酮
  参考文献：
  名称：

  [EN] SEROTONIN RECEPTOR-TARGETING COMPOUNDS AND METHODS
  [FR] COMPOSÉS DE CIBLAGE DE RÉCEPTEUR DE SÉROTONINERGIQUE ET PROCÉDÉS ASSOCIÉS

  摘要：

  这项发明涉及部分用于治疗各种疾病的组合物和方法，其中这些疾病与在血清素受体上的结合有关。这些组合物包括手性四氢萘-2-胺衍生物。因此，本发明提供了用于激动或拮抗一个或多个血清素受体的组合物和方法，这些组合物和方法可用于治疗各种神经精神疾病或障碍，包括但不限于孤独症谱系障碍（ASD）或相关症状。

  公开号：

  WO2015179366A1
• 作为产物：
  描述：

  邻溴氰苄 在 氢氧化钾 、 lithium aluminium tetrahydride 、 三氯化铝 、 氯化亚砜 、 硫酸 、 氢溴酸 、 sodium ethanolate 作用下， 以 二硫化碳 、 乙醚 、 乙醇 、 水 为溶剂， 反应 24.75h， 生成 5-溴-1-四氢萘酮
  参考文献：
  名称：

  Synthesis of biological markers in fossil fuels. 2. Synthesis and carbon-13 NMR studies of substituted indans and tetralins

  摘要：

  DOI：

  10.1021/jo00196a024

文献信息

• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2017205538A1

  公开（公告）日：2017-11-30

  The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.

  本发明涉及一种化合物公式（I）及其盐，其中R1、R2X和Y具有本文中定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含公式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的疾病，如癌症、炎症性疾病和自身免疫疾病中使用这些化合物和盐的方法。
• [EN] BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS<br/>[FR] ANALOGUES DE BIARYL-SPIROAMINOOXAZOLINE EN TANT QUE MODULATEURS DE RÉCEPTEUR ADRÉNERGIQUE ALPHA2C
  申请人：SCHERING CORP

  公开号：WO2010042473A1

  公开（公告）日：2010-04-15

  In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

  本发明的多种实施例提供了一类新型的双芳基螺氨氧杂萘类衍生物，作为α2C肾上腺素受体激动剂的调节剂，提供了制备这类化合物的方法，包含一个或多个这类化合物的药物组合物，制备包含一个或多个这类化合物的药物制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体相关的一个或多个条件的方法。
• [EN] MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE HSD17B13 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2021003295A1

  公开（公告）日：2021-01-07

  The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

  本公开涉及能够调节羟基类固醇17-β脱氢酶（HSD17B）家族成员蛋白的化合物和药物组合物，包括抑制HSD17B家族成员蛋白，例如HSD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法，其中HSD17B家族成员蛋白发挥作用。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2017023679A1

  公开（公告）日：2017-02-09

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在某些实施例中提供了一些符合本文所定义的A式化合物，其调节5-HT2C受体的活性。在某些实施例中还提供了一些方法，例如用于体重管理、诱导饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理性赌博、奖赏缺乏综合征和性成瘾，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱），尿失禁，精神障碍（包括精神分裂症、厌食症和暴食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森病和抗精神病药物引起的运动障碍），高血压，血脂异常，非酒精性脂肪肝病，肥胖相关肾脏疾病和睡眠呼吸暂停症。